Tag: ADC manufacturing
How Process Enabling Closed Systems Offer Maximum Safety in ADC Manufacturing
Since Antibody-drug Conjugates (ADC) are already approved for the treatment of relapsed Hodgkin’s lymphoma, HER2-positive metastatic breast cancer and B cell lymphoma, among others, high expectations are placed on this class of bioconjugates. Indeed, more than 100 different ADCs have been studied for various applications by 2022, presumably with several more to follow.
Automating ADC Manufacturing with Electricity
Combining the specificity and stability of antibodies with the potency of small molecules has always been at the core of the antibody drug conjugate (ADC) field. The technological challenge to this therapeutic approach is in bringing two disparate molecules in union with one another. Once this was achieved, the next technological hurdle was, in essence, automation
Opportunities for ADC Development and Manufacturing
At the 2022 World ADC Conference in San Diego, Stewart Mitchell, Executive Vice President and site head of Sterling Pharma Solutions' Deeside, U.K. facility, presented a case study on the development and GMP manufacture at the site.
A New Horizon in ADC Technology: A Panel Discussion
Targeted therapies such as antibody-drug conjugates (ADC) have opened new ways in targeting diseases like cancer and hematological malignancies. High-potent active pharmaceutical ingredients, also...
How a CDMO can Support ADC Manufacturing
Over the last decades, outsourcing of pharmaceutical development and manufacturing, driven by a variety of factors, has resulted in the growth of Contract Development...
Creating a New Single-digit Nanogram Containment Manufacturing Facility: MilliporeSigma Announces US...
In a statement today, MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany, confirmed a US $65 million (€ 59 million) investment in...
Download the Application Note on the Pellicon® Capsule
Tangential flow filtration (TFF) is essential in the manufacturing of antibody drug conjugates (ADCs). Ultrafiltration (UF) is used to concentrate the protein product and...
Investing for the Future: Unlocking Advanced ADC Manufacturing Innovation
UPDATE: This event has been postponed until Fall 2019.
Investment in ADCs (antibody-drug conjugates) has surged due to some very compelling market trends that include: ...
ADC Biotechnology Secures UK £1.14 million Investment
ADC Biotechnology has successfully secured UK £1.14 million in funding from, Downing LLP, a London-based investment management firm.
The company, founded in 2010, is developing...
Ajinomoto Althea Expected to Open New Manufacturing Facility for Antibody-drug Conjugate...
Biopharmaceutical contract development and manufacturing services company, Ajinomoto Althea confirmed that announced it will soon open a GMP production suite in its newly constructed...
